Ms. Krasner has extensive expertise in federal healthcare programs  in areas including Medicare coverage,  pharmaceutical reimbursement, and  Medicare and Medicaid  managed care arrangements. In particular she has a unique expertise with regard to the  legal, regulatory and policy implications of the Medicare prescription drug benefit. She also is now spending a lot of time on a wide range of health reform interpretation and implementation issues.  

Prior to joining Manatt, Ms. Krasner worked as Deputy Vice President for Policy at the Pharmaceutical  Research and Manufacturers of America (the trade association for brand-name pharmaceutical manufacturers known as PhRMA).  There, she played a prominent role in the development of the new Medicare prescriptsion drug benefit. Before joining PhRMA in 2003, she was a partner in the  Washington, D.C. office of McDermott Will & Emery, where she practiced  healthcare law for over 23 years.

University of California, Berkeley, Boalt Hall School of Law, J.D., 1978.
Order of the Coif.

Harvard University, B.A., cum laude, 1975.

Admitted to practice in the state of California and the District of Columbia.

Chair, Life Sciences Practice Group, American Health Lawyers Association.

Member, Editorial Advisory Board, BNA Life Sciences Law & Industry Report,
2007-present.

Member, BNA Health Plan and Provider Advisory Board, 2000-present.

Member, Editorial Advisory Board, United States Health Care Laws and Rules, 2002-2003, 2004-2005, and 2006-2007 editions.

Board Member, Cradle of Hope (International Adoption Agency), 1995-1999.

Board Member, Visiting Nurse Association of Washington, D.C., 1990-1995.

Instructor, Johns Hopkins School of Medicine, 1995-1998.

Leading U.S. Healthcare Lawyers, 2005. 

Best Health Lawyers in U.S., 1997-1998, 1999-2000, 2001-2002, 2003-2004.

Co-Author, “Affordable Care Act Provisions in the 2011 Medicare Physician Fee Rule,” BNA’s Medicare Report, July 23, 2010.

Contributor, “The Implications of Obama’s Executive Order on the Study of Embryonic Stem Cells,” BNA’s Medical Research Law & Policy Report, 8 MRLR 253, April 1, 2009.

Co-Author, “Significant Federal Endorsement of Incentive Payments to Drive E-Prescribing Adoption,” BNA’s Health Plan & Provider Report 14(30), July 16, 2008.

Contributor, “Federal Preemption:  U.S. High Court Cases Leave Circuits Split on Fraud-on-FDA, Attorneys Say Congress May Have to Revisit Preemption Issue,” BNA’s Life Sciences Law & Industry Report 2(6), March 14, 2008.

Co-Author, “Medicare Part D Compliance,” 2008 Health Law and Compliance Update, Aspen Publishers, 2008.

Contributor, “Insurance Reform, Access, Medicare Advantage, Health IT Issues Loom in 2008,” BNA’s Health Plan & Provider Report 14(3), January 16, 2008.

Contributor, “Experts Predict Which Life Sciences Issues Will Predominate in 2008,” BNA’s Life Sciences Law & Industry Report 2(1), January 4, 2008.

Co-Author, “Private Medicare Drug Plans:  High Expenses and Low Rebates Increase the Costs of Medicare Drug Coverage,” Life Sciences Practice Group E-mail Alert, American Health Lawyers Association, October 16, 2007.

Co-Author, “Vaccine Administration and Access Update:  Beneficiaries to Receive Greater Access to Vaccines in 2008,” BNA's Life Sciences Law & Industry Report1(13), September 14, 2007.

Co-Author, “Part D Formularies:  The Ongoing Battleground between Access and Cost,” Chapter in Health Law Handbook, Thompson/West, May 2007.

Co-Author, “CMS Issues 2008 Part D Vaccine Guidance Summary,” Life Sciences Practice Group E-mail Alert, American Health Lawyers Association, May 15, 2007.

Co-Author, “Summary of Baucus Proposed Legislation to Strike the Non-Interference Clause,” Life Sciences Practice Group E-mail Alert, American Health Lawyers Association, April 11, 2007.

Co-Author, “New Developments in Part D Vaccine Administration and Access,” Health Plan & Provider Report 13(2), January 10, 2007.

Co-Author, “Key Changes Made in Final Chapter 9 of the Prescription Drug Benefit Manual,” Health Lawyers Weekly, May 5, 2006.

Co-Author, “Client Advisory - CMS Releases Draft Fraud Waste and Abuse Chapter for the Prescription Drug Benefit Manual,” Manatt, Phelps & Phillips, LLP, February 2006.

Co-Author, “Client Advisory - Significant Changes to Medicaid in Federal Deficit Reduction action of 2005,” Manatt, Phelps & Phillips, LLP, February 2006.

Co-Author, “Part D Challenges,” Health Lawyers Weekly, October 28, 2005.

Co-Author, “6.4 Million at Risk:  Protecting the Poorest Americans During the Medicare Drug Transition,” Medicare Rights Center, October 2005.

Co-Author, “Medicaid Managed Care Final Rules,” AHLA HMOs and Health Plans Practice Group:  Member Briefing.

“Plan Liability:  Good News and Bad News From First Major Florida MDL Ruling,” Managed Care Law Strategist.

“Medicare+Choice:  Regulations, Contracts, and Policies,” Health Law Handbook.

“Medicare Outpatient Prescription Drug Benefits:  Lessons Learned from M+C?” BNA’s Medicare Report.

“Integrating Accreditation Activities into Your Compliance Program,?” Today’s Corporate Compliance.

“Implications of Compliance with QISMC,?” Today’s Corporate Compliance.

“OIG Draft Compliance Program Guidance for Medicare+Choice Organizations,?” Today’s Corporate Compliance.

“Compliance Uncertainty: How to Proceed in an Unpredictable Regulatory Environment,?” Today’s Corporate Compliance.